Skip to content
Screener

Pacific Biosciences of California PACB Business Segments — Income tax provision (benefit)

Similar metrics at other companies

Chewy logo
CHWYReportable Segment — Income tax provision (benefit)
$36.5M+135%
Cronos Group logo
CRONReportable Segment — Income tax provision (benefit)
$51K+110%
Inseego Corp. logo
INSGReportable Segment — Income tax provision (benefit)
$35K+59.1%
DraftKings Inc. logo
DKNGReportable Segment — Income tax provision (benefit)
-$1.8M-115%
ConocoPhillips logo
COPAlaska Segment — Income tax provision (benefit)
$159M+238%
ConocoPhillips logo
COPTotal Segments — Income tax provision (benefit)
$2.13B+86.8%

Other financials

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$357.46M-5.6%
Enterprise value$356.64M-4.8%
P/S2.2×-0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gain on disposal of assets(45,796)
Change in fair value of contingent consideration(18,700)
Amortization of acquired intangible assets8338331,666362,875
Operating loss(44,610)(44,853)(52,967)(473,787)
Other (expense) income, net(73)2,9581935,515
Loss before income taxes(44,683)(41,895)(52,774)(468,272)
Income tax provision (benefit)5835242(267)
Net loss$(44,741)$(41,930)$(53,016)$(468,005)

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's business segments — income tax provision (benefit)?
Pacific Biosciences of California (PACB) reported business segments — income tax provision (benefit) of $58K in Q2 2026.
How has Pacific Biosciences of California's business segments — income tax provision (benefit) changed year-over-year?
Pacific Biosciences of California's business segments — income tax provision (benefit) increased by 65.7% year-over-year, from $35K to $58K.
What does business segments — income tax provision (benefit) mean?
This reflects the total tax expense or benefit recognized by the reportable segment for the period, calculated based on applicable jurisdictional tax laws. It represents the portion of the company's tax burden or credit attributable to the specific operations of this segment. Analyzing this figure is essential for understanding the segment's effective tax rate and its contribution to the company's overall tax position.

Ask your AI about Pacific Biosciences of California's business segments — income tax provision (benefit).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude